{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:27Z","timestamp":1794047487424,"version":"4.8.0"},"reference-count":46,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Whereas immunotherapies have revolutionized the treatment of different solid and hematologic cancers, their efficacy in nodal peripheral T-cell lymphomas (PTCL) is limited, due to a lack of understanding of the immune response they trigger. To fully characterize the immune tumor microenvironment (TME) of PTCL, we performed spectral flow cytometry analyses on 11 angioimmunoblastic T-cell lymphomas (AITL), 7 PTCL, not otherwise specified (PTCL, NOS) lymph node samples, and 10 non-tumoral control samples. The PTCL TME contained a larger proportion of regulatory T cells and exhausted CD8+ T cells, with enriched expression of druggable immune checkpoints. Interestingly, CD39 expression was up-regulated at the surface of most immune cells, and a multi-immunofluorescence analysis on a retrospective cohort of 43 AITL patients demonstrated a significant association between high CD39 expression by T cells and poor patient prognosis. Together, our study unravels the complex TME of nodal PTCL, identifies targetable immune checkpoints, and highlights CD39 as a novel prognostic factor.<\/jats:p>","DOI":"10.3324\/haematol.2023.284448","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T08:25:19Z","timestamp":1717057519000},"page":"129-141","source":"Crossref","is-referenced-by-count":6,"title":["Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets"],"prefix":"10.3324","volume":"110","author":[{"given":"Pierre","family":"Stephan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Voisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Barbery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Andrieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Grimont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Caramel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Bardou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garance","family":"Tondeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Missiaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lemmonier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"De Leval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sujobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Genestier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Traverse-Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenkel","family":"Grinberg-Bleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"70936","doi-asserted-by":"crossref","unstructured":"Campo E, Jaffe ES, Cook JR. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140(11):1229-1253.","DOI":"10.1182\/blood.2022015851"},{"key":"70937","doi-asserted-by":"crossref","unstructured":"Fujisawa M, Chiba S, Sakata-Yanagimoto M. Recent progress in the understanding of angioimmunoblastic T-cell lymphoma. J Clin Exp Hematop. 2017; 57(3):109-119.","DOI":"10.3960\/jslrt.17019"},{"key":"70938","doi-asserted-by":"crossref","unstructured":"de Leval L, Parrens M, Le Bras F. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica. 2015; 100(9):e361-364.","DOI":"10.3324\/haematol.2015.126300"},{"key":"70939","doi-asserted-by":"crossref","unstructured":"Armand P, Shipp MA, Ribrag V. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016; 34(31):3733-3739.","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"70940","doi-asserted-by":"crossref","unstructured":"Ansell SM, Lesokhin AM, Borrello I. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015; 372(4):311-319.","DOI":"10.1056\/NEJMoa1411087"},{"key":"70941","doi-asserted-by":"crossref","unstructured":"Bennani NN, Kim HJ, Pederson LD. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer. 2022; 10(6):e004984.","DOI":"10.1136\/jitc-2022-004984"},{"key":"70942","doi-asserted-by":"crossref","unstructured":"Shi Y, Wu J, Wang Z. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). J Hematol Oncol. 2021; 14(1):12.","DOI":"10.1186\/s13045-021-01033-1"},{"key":"70943","doi-asserted-by":"crossref","unstructured":"Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018; 378(20):1947-1948.","DOI":"10.1056\/NEJMc1803181"},{"key":"70944","doi-asserted-by":"crossref","unstructured":"Wartewig T, Kurgyis Z, Keppler S. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017; 552(7683):121-125.","DOI":"10.1038\/nature24649"},{"key":"70945","doi-asserted-by":"crossref","unstructured":"Wilcox RA, Wada DA, Ziesmer SC. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood. 2009; 114(14):2936-2944.","DOI":"10.1182\/blood-2009-05-220111"},{"key":"70946","doi-asserted-by":"crossref","unstructured":"Ham JS, Park HY, Ryu KJ, Ko YH, Kim WS, Kim SJ. Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. Oncotarget. 2017; 8(44):76231-76240.","DOI":"10.18632\/oncotarget.19301"},{"key":"70947","doi-asserted-by":"crossref","unstructured":"Sugio T, Miyawaki K, Kato K. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. Blood Adv. 2018; 2(17):2242-2252.","DOI":"10.1182\/bloodadvances.2018018754"},{"key":"70948","doi-asserted-by":"crossref","unstructured":"Zhu Q, Deng X, Yao W. Novel tumour-infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de novo angioimmunoblastic T cell lymphoma. Ann Hematol. 2021; 100(3):715-723.","DOI":"10.1007\/s00277-020-04389-5"},{"key":"70949","doi-asserted-by":"crossref","unstructured":"Chen Z, Zhu Q, Deng X. Angioimmunoblastic T-cell lymphoma with predominant CD8+ tumor-infiltrating T-cells is a distinct immune pattern with an immunosuppressive microenvironment. Front Immunol. 2022; 13:987227.","DOI":"10.3389\/fimmu.2022.987227"},{"key":"70950","doi-asserted-by":"crossref","unstructured":"Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?. Cancer Sci. 2019; 110(7):2080-2089.","DOI":"10.1111\/cas.14069"},{"key":"70951","doi-asserted-by":"crossref","unstructured":"Lundberg J, Berglund D, Molin D, Kinch A. Intratumoral expression of FoxP3-positive regulatory T-cells in T-cell lymphoma: no correlation with survival. Ups J Med Sci. 2019; 124(2):105-110.","DOI":"10.1080\/03009734.2018.1555195"},{"key":"70952","doi-asserted-by":"crossref","unstructured":"Bruneau J, Canioni D, Renand A. Regulatory T-cell depletion in angioimmunoblastic T-cell lymphoma. Am J Pathol. 2010; 177(2):570-574.","DOI":"10.2353\/ajpath.2010.100150"},{"key":"70953","doi-asserted-by":"crossref","unstructured":"Pritchett JC, Yang ZZ, Kim HJ. High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL). Leukemia. 2022; 36(1):165-176.","DOI":"10.1038\/s41375-021-01321-2"},{"key":"70954","doi-asserted-by":"crossref","unstructured":"Gaulard P, de Leval L. Follicular helper T cells: implications in neoplastic hematopathology. Semin Diagn Pathol. 2011; 28(3):202-213.","DOI":"10.1053\/j.semdp.2011.03.003"},{"key":"70955","doi-asserted-by":"crossref","unstructured":"Judge SJ, Dunai C, Aguilar EG. Minimal PD-1 expression in mouse and human NK cells under diverse conditions. J Clin Invest. 2020; 130(6):3051-3068.","DOI":"10.1172\/JCI133353"},{"key":"70956","doi-asserted-by":"crossref","unstructured":"Moesta AK, Li XY, Smyth MJ. Targeting CD39 in cancer. Nat Rev Immunol. 2020; 20(12):739-755.","DOI":"10.1038\/s41577-020-0376-4"},{"key":"70957","doi-asserted-by":"crossref","unstructured":"Fujisawa M, Nguyen TB, Abe Y. Clonal germinal center B cells function as a niche for T-cell lymphoma. Blood. 2022; 140(18):1937-1950.","DOI":"10.1182\/blood.2022015451"},{"key":"70958","doi-asserted-by":"crossref","unstructured":"Delfau-Larue MH, de Leval L, Joly B. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica. 2012; 97(10):1594-1602.","DOI":"10.3324\/haematol.2011.061507"},{"key":"70959","doi-asserted-by":"crossref","unstructured":"Querfeld C, Leung S, Myskowski PL. Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile. Cancer Immunol Res. 2018; 6(8):900-909.","DOI":"10.1158\/2326-6066.CIR-17-0270"},{"key":"70960","doi-asserted-by":"crossref","unstructured":"Heming M, Haessner S, Wolbert J. Intratumor heterogeneity and T cell exhaustion in primary CNS lymphoma. Genome Med. 2022; 14(1):109.","DOI":"10.1186\/s13073-022-01110-1"},{"key":"70961","doi-asserted-by":"crossref","unstructured":"Yang ZZ, Liang AB, Ansell SM. T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion. Leuk Lymphoma. 2015; 56(9):2498-2504.","DOI":"10.3109\/10428194.2015.1011640"},{"key":"70962","doi-asserted-by":"crossref","unstructured":"Ansell SM, Lin Y. Immunotherapy of lymphomas. J Clin Invest. 2020; 130(4):1576-1585.","DOI":"10.1172\/JCI129206"},{"key":"70963","doi-asserted-by":"crossref","unstructured":"Li X, Liu Z, Mi M. Identification of hub genes and key pathways associated with angioimmunoblastic T-cell lymphoma using weighted gene co-expression network analysis. Cancer Manag Res. 2019; 11:5209-5220.","DOI":"10.2147\/CMAR.S185030"},{"key":"70964","doi-asserted-by":"crossref","unstructured":"Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020; 13(1):45.","DOI":"10.1186\/s13045-020-00876-4"},{"key":"70965","doi-asserted-by":"crossref","unstructured":"Sharma A, Subudhi SK, Blando J. Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers-Response. Clin Cancer Res. 2019; 25(11):3469-3470.","DOI":"10.1158\/1078-0432.CCR-19-0402"},{"key":"70966","doi-asserted-by":"crossref","unstructured":"Quezada SA, Peggs KS. Lost in translation: deciphering the mechanism of action of anti-human CTLA-4. Clin Cancer Res. 2019; 25(4):1130-1132.","DOI":"10.1158\/1078-0432.CCR-18-2509"},{"key":"70967","doi-asserted-by":"crossref","unstructured":"Ha D, Tanaka A, Kibayashi T. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc Natl Acad Sci U S A. 2019; 116(2):609-618.","DOI":"10.1073\/pnas.1812186116"},{"key":"70968","doi-asserted-by":"crossref","unstructured":"Semmrich M, Marchand JB, Fend L. Vectorized Treg-depleting alphaCTLA-4 elicits antigen cross-presentation and CD8(+) T cell immunity to reject \u2018cold\u2019 tumors. J Immunother Cancer. 2022; 10(1):e003488.","DOI":"10.1136\/jitc-2021-003488"},{"key":"70969","doi-asserted-by":"crossref","unstructured":"Nicholson SM, Carlesso G, Cheng LI. Effects of ICOS+ T cell depletion via afucosylated monoclonal antibody MEDI-570 on pregnant cynomolgus monkeys and the developing offspring. Reprod Toxicol. 2017; 74:116-133.","DOI":"10.1016\/j.reprotox.2017.08.018"},{"key":"70970","doi-asserted-by":"crossref","unstructured":"Chavez JC, Foss FM, MD William BM. A phase I study of anti-ICOS antibody MEDI-570 for relapsed \/ refractory (R\/R) peripheral T-cell lymphoma (PTCL) and angioimmunoblastic T-cell lymphoma (AITL) (NCI-9930). Blood. 2020; 136(Suppl 1):5-6.","DOI":"10.1182\/blood-2020-136465"},{"key":"70971","doi-asserted-by":"crossref","unstructured":"van Hall T, Andre P, Horowitz A. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019; 7(1):263.","DOI":"10.1186\/s40425-019-0761-3"},{"key":"70972","doi-asserted-by":"crossref","unstructured":"Perrot I, Michaud HA, Giraudon-Paoli M. Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep. 2019; 27(8):2411-2425.e9.","DOI":"10.1016\/j.celrep.2019.04.091"},{"key":"70973","doi-asserted-by":"crossref","unstructured":"Nagate Y, Ezoe S, Fujita J. Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function. Leukemia. 2021; 35(1):107-118.","DOI":"10.1038\/s41375-020-0788-y"},{"key":"70974","doi-asserted-by":"crossref","unstructured":"Bensussan A, Janela B, Thonnart N. Identification of CD39 as a marker for the circulating malignant T-cell clone of Sezary syndrome patients. J Invest Dermatol. 2019; 139(3):725-728.","DOI":"10.1016\/j.jid.2018.09.026"},{"key":"70975","doi-asserted-by":"crossref","unstructured":"Nakamura K, Casey M, Oey H. Targeting an adenosinemediated \u201cdon\u2019t eat me signal\u201d augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. Leukemia. 2020; 34(10):2708-2721.","DOI":"10.1038\/s41375-020-0811-3"},{"key":"70976","doi-asserted-by":"crossref","unstructured":"Yang R, Elsaadi S, Misund K. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. J Immunother Cancer. 2020; 8(1):e000610.","DOI":"10.1136\/jitc-2020-000610"},{"key":"70977","doi-asserted-by":"crossref","unstructured":"Perry C, Hazan-Halevy I, Kay S. Increased CD39 expression on CD4(+) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia. Ann Hematol. 2012; 91(8):1271-1279.","DOI":"10.1007\/s00277-012-1425-2"},{"key":"70978","doi-asserted-by":"crossref","unstructured":"Aroua N, Boet E, Ghisi M. Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid Leukemia. Cancer Discov. 2020; 10(10):1544-1565.","DOI":"10.1158\/2159-8290.CD-19-1008"},{"key":"70979","doi-asserted-by":"crossref","unstructured":"Li XY, Moesta AK, Xiao C. Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity. Cancer Discov. 2019; 9(12):1754-1773.","DOI":"10.1158\/2159-8290.CD-19-0541"},{"key":"70980","doi-asserted-by":"crossref","unstructured":"Hilchey SP, Kobie JJ, Cochran MR. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness. J Immunol. 2009; 183(10):6157-6166.","DOI":"10.4049\/jimmunol.0900475"},{"key":"70981","doi-asserted-by":"crossref","unstructured":"Sonigo G, Bozonnat A, Dumont M. Involvement of the CD39\/CD73\/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sezary syndrome. Blood. 2022; 139(17):2712-2716.","DOI":"10.1182\/blood.2021014782"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284448\/77102","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284448\/77945","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11617\/77102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:32Z","timestamp":1794045992000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284448","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}